Anson Funds Management LP bought a new stake in shares of Tenax Therapeutics Inc (NASDAQ:TENX) in the 4th quarter, Holdings Channel reports. The fund bought 607,097 shares of the specialty pharmaceutical company’s stock, valued at approximately $297,000.
Tenax Therapeutics Inc (NASDAQ TENX) opened at $8.19 on Wednesday. The firm has a market cap of $11.56, a P/E ratio of -0.31 and a beta of 1.69. Tenax Therapeutics Inc has a 1-year low of $4.40 and a 1-year high of $15.80.
Separately, ValuEngine raised shares of Tenax Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.
Want to see what other hedge funds are holding TENX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenax Therapeutics Inc (NASDAQ:TENX).
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.